Jason D Bush

US Patent:

7482167, Jan 27, 2009

Filed:

Mar 11, 2005

Appl. No.:

11/078998

Inventors:

Paul Sammak - Pittsburgh PA, US
Gustavo Rosania - Ann Arbor MI, US
Lawrence J. Zana - Gibsonia PA, US
Kim Ippolito - Pittsburgh PA, US
Jason Bush - Pittsburgh PA, US
Alex Friedman - Pittsburgh PA, US
Sarah Burroughs Tencza - Pittsburgh PA, US
Ravi Kapur - Gibsonia PA, US

Assignee:

Cellomics, Inc. - Pittsburgh PA

International Classification:

G01N 33/48

US Classification:

436164, 422 8207, 422 8208

Abstract:

The present invention provides a test plate and methods for adjusting fluorescence imaging systems involving using a plate with fluorescent microbeads bound to a surface.

US Patent:

20020098588, Jul 25, 2002

Filed:

Nov 30, 2001

Appl. No.:

09/997821

Inventors:

Paul Sammak - Pittsburgh PA, US
Gustavo Rosania - Ann Arbor MI, US
Lawrence Zana - Gibsonia PA, US
Kim Ippolito - Pittsburgh PA, US
Jason Bush - Pittsburgh PA, US
Alex Friedman - Pittsburgh PA, US
Sarah Tencza - Pittsburgh PA, US
Ravi Kapur - Gibsonia PA, US

International Classification:

G01N021/93

US Classification:

436/008000, 436/172000, 422/058000, 422/082080, 156/067000

Abstract:

The present invention provides a test plate and methods for adjusting fluorescence imaging systems involving using a plate with fluorescent microbeads bound to a surface.

US Patent:

20100216168, Aug 26, 2010

Filed:

Mar 24, 2008

Appl. No.:

12/530541

Inventors:

Jamie Heinzman - Pittsburgh PA, US
Stacey Brower - Pittsburgh PA, US
Jason Bush - Pittsburgh PA, US
Zhibao Mi - Pittsburgh PA, US

Assignee:

PRECISION THERAPEUTICS, INC. - Pitrsburgh PA

International Classification:

G01N 33/574

US Classification:

435 723

Abstract:

The present invention provides a method of evaluating the angiogenic potential of a tumor, and for predicting the efficacy of anti-angiogenic therapies on an individualized basis. The method of the invention involves preparing an angiogenic signature for malignant cells in culture by assaying for the presence or level of one or more angiogenesis-related factors selected from VEGF/VPF, IL8/CXCL8, TGF-β1, TGF-β2, TGF-β3, bFGF/FGF-2, EGF, PDGF-AA, PDGF-AA/BB, IP-10, and Flt-3 ligand. The angiogenic signature may be prepared from cultures maintained under normoxic and/or hypoxic environments. The invention may be used in conjunction with chemoresponse testing of anti-tumor agents, to predict or suggest a combination therapy for cancer patients.